OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX) in a report issued on Tuesday. The brokerage set a “sell” rating on the stock.

Separately, Needham & Company LLC reissued a “buy” rating and issued a $4.25 price objective on shares of OncoCyte in a report on Wednesday, November 13th.

OncoCyte Trading Down 2.6 %

Shares of OCX stock opened at $2.64 on Tuesday. OncoCyte has a one year low of $2.29 and a one year high of $4.30. The firm has a 50-day moving average of $2.97 and a 200-day moving average of $2.98.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.54). OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. The business had revenue of $0.12 million during the quarter. During the same period in the previous year, the business earned ($0.57) EPS.

Insider Activity

In related news, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was bought at an average cost of $2.95 per share, for a total transaction of $3,880,250.05. Following the completion of the transaction, the insider now owns 6,244,405 shares of the company’s stock, valued at approximately $18,420,994.75. The trade was a 26.69 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Andrea S. James acquired 33,670 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was purchased at an average price of $2.97 per share, with a total value of $99,999.90. Following the completion of the acquisition, the chief financial officer now directly owns 33,670 shares in the company, valued at approximately $99,999.90. This represents a ? increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.58% of the company’s stock.

Institutional Trading of OncoCyte

A hedge fund recently raised its stake in OncoCyte stock. Geode Capital Management LLC lifted its stake in OncoCyte Co. (NASDAQ:OCX) by 12.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 103,980 shares of the company’s stock after buying an additional 11,289 shares during the period. Geode Capital Management LLC owned approximately 0.62% of OncoCyte worth $296,000 as of its most recent SEC filing. 55.35% of the stock is owned by hedge funds and other institutional investors.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.